<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the case of a t(14:18)(+) follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) patient in long-term clinical remission after undergoing an allogeneic bone marrow transplantation (allo-BMT) from a human leukocyte antigen (HLA)-identical sibling donor who was the <z:mpath ids='MPATH_458'>normal</z:mpath> healthy carrier of a t(14:18)(+) B cell clone </plain></SENT>
<SENT sid="1" pm="."><plain>Using real-time quantitative PCR (RQ-PCR) and gel electrophoresis, we document the temporal disappearance of the patient's t(14:18)(+) clone early post-transplant with the concomitant emergence and long-term persistence of the donor's t(14:18)(+) clone in the patient's peripheral blood </plain></SENT>
<SENT sid="2" pm="."><plain>This report indicates that the use of PCR-based techniques to measure <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> in FL patients post-alloBMT should incorporate pretransplant screening of the donor for t(14;18) </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, it suggests that healthy individuals with t(14:18) need not be excluded as donors for FL patients treated with allo-BMT </plain></SENT>
</text></document>